Pharmacodynamics of carbapenems for the treatment of Pseudomonas aeruginosa ventilator-associated pneumonia: Associations with clinical outcome and recurrence

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 9, 2016, Pages 2534-2537

  Crandon, Jared L ^a   Luyt, Charles Edouard ^b   Aubry, Alexandra ^c   Chastre, Jean ^b   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

^b SORBONNE UNIVERSITÉ   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE; DORIPENEM; IMIPENEM; MEROPENEM; THIENAMYCIN DERIVATIVE;

ADULT; AGED; ANIMAL; DISK DIFFUSION; DRUG EFFECTS; FEMALE; HUMAN; MALE; MIDDLE AGED; PNEUMONIA, VENTILATOR-ASSOCIATED; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RECURRENT DISEASE; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTI-BACTERIAL AGENTS; CARBAPENEMS; DISK DIFFUSION ANTIMICROBIAL TESTS; FEMALE; HUMANS; IMIPENEM; MALE; MIDDLE AGED; PNEUMONIA, VENTILATOR-ASSOCIATED; PROSPECTIVE STUDIES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RECURRENCE; THIENAMYCINS; TREATMENT OUTCOME;

EID: 85011649467     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw200     Document Type: Article

References (20)

1. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 388-416.
2. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-10; quiz 11-2.
3. Drusano GL. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis 2003; 36 Suppl 1: S42-50.
4. Ong CT, Tessier PR, Li C et al. Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps. Diagn Microbiol Infect Dis 2007; 57: 153-61.
5. Credito K, Kosowska-Shick K, Appelbaum PC. Mutant prevention concentrations of four carbapenems against Gram-negative rods. Antimicrob Agents Chemother 2010; 54: 2692-5.
6. Dahdouh E, Shoucair SH, Salem SE et al. Mutant prevention concentrations of imipenem and meropenemagainst Pseudomonas aeruginosa and Acinetobacter baumannii. ScientificWorldJournal 2014; 2014: 979648.
7. Louie A, Grasso C, Bahniuk N et al. The combination of meropenem and levofloxacin is synergistic with respect to both Pseudomonas aeruginosa kill rate and resistance suppression. Antimicrob Agents Chemother 2010; 54: 2646-54.
8. TamVH, Schilling AN, Neshat S et al.Optimization ofmeropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005; 49: 4920-7.
9. Luyt CE, Aubry A, Lu Q et al. Imipenem, meropenem, or doripenem to treat patients with Pseudomonas aeruginosa ventilator-associated pneumonia. Antimicrob Agents Chemother 2014; 58: 1372-80.
10. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-fourth Informational Supplement M100-S24. CLSI, Wayne, PA, USA, 2014.
11. Crandon JL, Bulik CC, Kuti JL et al. Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa. Antimicrob Agents Chemother 2010; 54: 1111-6.
12. MacVane SH, Kuti JL, Nicolau DP. Clinical pharmacodynamics of antipseudomonal cephalosporins in patients with ventilator-associated pneumonia. Antimicrob Agents Chemother 2014; 58: 1359-64.
13. Ikawa K, Morikawa N, Uehara S et al. Pharmacokineticpharmacodynamic target attainment analysis of doripenem in infected patients. Int J Antimicrob Agents 2009; 33: 276-9.
14. Crandon JL, Ariano RE, Zelenitsky SA et al. Optimization of meropenem dosage in the critically ill population based on renal function. Intensive Care Med 2011; 37: 632-8.
15. Couffignal C, Pajot O, Laouenan C et al. Population pharmacokinetics of imipenem in critically ill patients with suspected ventilator-associated pneumonia and evaluation of dosage regimens. Br J Clin Pharmacol 2014; 78: 1022-34.
16. Bowker KE, Noel AR, Tomaselli SG et al. Pharmacodynamics of the antibacterial effect of and emergence of resistance to doripenem in Pseudomonas aeruginosa and Acinetobacter baumannii in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 2012; 56: 5009-15.
17. Li X, Wang L, Zhang XJ et al. Evaluation of meropenem regimens suppressing emergence of resistance in Acinetobacter baumannii with human simulated exposure in an in vitro intravenous-infusion hollow-fiber infection model. Antimicrob Agents Chemother 2014; 58: 6773-81.
18. Louie A, Liu W, VanGuilder M et al. Combination treatment with meropenem plus levofloxacin is synergistic against Pseudomonas aeruginosa infection in a murine model of pneumonia. J Infect Dis 2015; 211: 1326-33.
19. Muller AE, Punt N, Mouton JW. Exposure to ceftobiprole is associated with microbiological eradication and clinical cure in patients with nosocomial pneumonia. Antimicrob Agents Chemother 2014; 58: 2512-9.
20. Rubino CM, Bhavnani SM, Forrest A et al. Pharmacokineticspharmacodynamics of tigecycline in patients with community-acquired pneumonia. Antimicrob Agents Chemother 2012; 56: 130-6.